Pharma Q2 Earnings Preview - IPM To Drive Growth, U.S. On Slow Progression: Prabhudas Lilladher
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Prabhudas Lilladher Report
We expect Q2 FY22E revenue/Ebitda/profit before tax of pharma companies under our coverage to grow by 5%/11%/12% YoY, while diagnostic companies to report 20%/17%/17% YoY growth.
Growth is largely driven by increased traction in domestic market and robust growth from Ex-U.S./Europe market.
Declining Covid-19 portfolio revenue is indicating higher normalisation in the economy thereby resulting in opening up of travel destinations and other major segments.
We believe that ease in RT/PCR tests will remain intact, while demand for core tests may increase with digitalisation in diagnostic segment.
Similarly, as vaccination ratio improves, less impact is expected from newer Covid-19 wave.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.